Heat Biologics Inc (NASDAQ: HTBX) is a US-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer, utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT) form the basis of its product candidates.

Key highlights 

• Recently the Company completed its gp96-based COVID-19 vaccine cell line ("ZVX-60"), which is being developed for use as either a standalone vaccine or in combination with other vaccines to enhance prophylactic protection. Given its vaccine platform's utility and versatility, the Company looks forward to advancing ZVX-60 into clinical development.

• The Company is encouraged by the recent Phase 3 data reported by other vaccine developers and commended the FDA for their fast action to accelerate approval. Notably, the group believe ZVX-60 holds promise as an adjunct therapy to enhance the protection provided by other vaccine approaches. 

• The group is applying for several large grants to support clinical development and are engaged in collaboration discussions, which the group believe may provide attractive and nondilutive pathways to help accelerate development of their COVID-19 program; however, there can be no assurance that they will receive such grant funding or if received, the amount of such grant funding. 

• The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrolment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. Besides, they are also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which enrols in a Phase 1 trial. The table below reflects the products at different stages.

Source: Company 

Financial overview of Q3 2020

Source: Company 

• The company recognized USD 0.85 million of grant revenue for qualified expenditures under the CPRIT grant and NIH grant in Q3 2020. This grant revenue primarily reflects the expected timing of completion of deliveries under the contracts' current phase.

• The general and administrative expense was USD 6.6 million in Q3 2020, compared to USD 2.0 million in the previous corresponding period. The significant increase was primarily due to stock-compensation expense.

• The company reported a net loss of USD 8.9 million, in Q3 2020 compared to a net loss of USD 6.2 million in Q3 2019. The rise in net loss was primarily due to higher G&A expenses. 

Key risks associated with investment

If the COVID-19 pandemic continues and persists for an extended period, the Company could experience significant disruptions to its clinical development timeline, which would adversely affect their business, financial condition, results of operations and growth prospects. 

Stock recommendation

Recently the company has completed its gp96-based COVID-19 vaccine cell line ("ZVX-60"), which is being developed for use as either a standalone vaccine or in combination with other vaccines to enhance prophylactic protection. The company is in the clinical trial stage and yet to receive any approval. Further, the management expects to continue to generate operating losses and experience negative cash flows, and it is uncertain to predict the time of profitability. Therefore, based on the aforementioned facts, and risks involved, we recommend an "Avoid" rating on the stock at the closing price of USD 6.34 as on 15 January 2021.

Source: Refinitiv (Thomson Reuters)

Disclaimer  

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as personalised advice.